





Dyno-bn8:
our solution for safe and
therapeutic delivery
of muscle gene
therapies

Wild-type AAVs do not achieve therapeutic muscle delivery except at high doses, introducing substantial safety risks



The capsids we need

Safer

More effective


Cheaper

Therapeutic delivery with **Dyno-bn8**,
at an unprecedented low dose of 5.2e12 vg/kg in NHPs

NHP gastrocnemius

NHP diaphragm

Dyno-bn8 achieves therapeutic delivery at a low dose, improving safety and reducing costs




Dyno-bn8:

Safer


More effective

Cheaper

We compared **Dyno-bn8** head-to-head in NHPs
with a published capsid, MyoAAV-4E




AAV capsid packaging
CBh-**mCherry** genome
with ssAAV ITRs






3 Adult Cyno NHPs
2 NHPs: 5.2e12 vg/kg
1 NHP: 1.6e13 vg/kg
28 days in life

5.2e12 vg/kg is 25x lower than Elevidys (1.33e14 vg/kg)

Dyno-bn8 outperforms MyoAAV-4E in muscle, heart, and liver







Dyno-bn8 outperforms MyoAAV-4E in muscle, heart, and liver





error bars
show 95% CI

Dyno-bn8 shows dose-responsive delivery in NHPs



At 5.2×10^{12} vg/kg, **Dyno-bn8** evenly transduces the vast majority of skeletal myofibers in all tested tissues




At 1.6×10^{13} vg/kg, **Dyno-bn8** transduces up to 95% of skeletal myofibers in the quadriceps





WGA, mCherry (Dyno-bn8), DAPI

Scale = 200 μ m





error bars
show 95% CI

At 5.2×10^{12} vg/kg, **Dyno-bn8** delivery to ventricular cardiomyocytes remains efficient



error bars
show 95% CI


At 1.6×10^{13} vg/kg, **Dyno-bn8** evenly transduces cardiomyocytes across three ventricular walls within the heart



error bars
show 95% CI


At 5.2×10^{12} vg/kg, **Dyno-bn8** delivers efficiently to facial muscles, key targets for disorders such as FSHD

orbicularis oculi




WGA, mCherry (Dyno-bn8), DAPI

orbicularis oris



Scale = 50 μ m

Dyno-bn8 transduces satellite cells, positioning it as a promising candidate for gene editing applications




WGA, **PAX7**, **mCherry (Dyno-bn8)**, **DAPI**
5.2e12 vg/kg IV


Scale = 10 μ m

Dyno-bn8 utilizes a conserved, non-RGD-based mechanism, increasing confidence in successful translation to humans


Human and mouse muscle cell lines are transduced by Dyno-bn8 in vitro



Identified human receptor mediates Dyno-bn8 transduction in vitro



Dyno-bn8 achieves therapeutic delivery to muscle at significantly lower doses* and with improved liver detargeting



*25x lower than Elevidys (1.33e14 vg/kg)



Dyno-bn8

available now

**for your muscle
gene therapies**